Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

New tool may predict best treatment for multiple myeloma

In 1844, multiple myeloma was first treated with a rhubarb pill and an infusion of orange peel. Since then, more than 15 drugs have earned FDA approval to treat multiple myeloma and with so many options, a major question has become what cocktail and sequence is best?

29 May 2020

How comorbidities affect SARS-CoV-2 viral entry

Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.

28 May 2020

Oncologists highlight the need for more palliative care training

Oncologists who practice and teach at the Johns Hopkins Kimmel Cancer Center are calling on medical oncology training programs to invest substantially more time educating physicians about palliative care and how to talk to patients about "bad news."

28 May 2020

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. T

20 May 2020

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable parts of the body. Now, a City of Hope molecular scientist thinks he may have found a way to prevent ineffective surgeries and prolong the lives of these patients.

18 May 2020

HVTN and HPTN initiate first clinical trial in response to COVID-19

The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) have initiated their first clinical trial in response to COVID-19.

15 May 2020

A 'window of vulnerability' for re-infection with HIV after stem cell transplantation

Some people with HIV need to undergo an allogeneic stem cell transplantation in order to treat different types of blood cancer. Most of the patient's immune cells are eliminated during these transplantations.

14 May 2020

Pediatric cancer patients are not at higher risk for COVID-19 infection, study finds

Researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) found that children with cancer are not at a higher risk of being affected by COVID-19.

13 May 2020

New discovery may contribute to early identification of aggressive breast tumors

Immune system cells in the blood of breast cancer patients undergo alterations early in the disease course, according to a study published in the journal Clinical & Translational Immunology.

12 May 2020

Clinical trial to test the efficacy of defibrotide medicine for reducing COVID-19 death rate

The Neurosciences Institute, mixed centre of the Spanish National Research Council and the Miguel Hernández University of Elche, have collaborated on the first clinical trial conducted in the world to test whether the defibrotide medicine, which has already been authorized to treat a severe obstruction of the hepatic sinusoidal veins of people who have undergone a bone marrow transplant, can be used as therapy against COVID-19.

12 May 2020

Fred Hutch, NIH experts outline an efficient approach to creating COVID-19 vaccines

Unprecedented collaboration and resources will be required to research and develop safe and effective vaccines for COVID-19 that can be manufactured and delivered in the scale of billions of doses to people globally.

11 May 2020

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

More selective elimination of leukemic and hematopoietic stem cells

Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.

8 May 2020

Scientists identify unexpected player that causes vision loss in patients with AMD

Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published today in eLife.

6 May 2020

Scientists receive $12-million grant to explore molecular mechanisms of heart injury and repair

Heart disease is a leading cause of death worldwide. But significant disparities exist in the incidence and severity of heart disease, particularly between men and women, and major barriers remain for the successful long-term care of heart disease patients.

5 May 2020

Inventor of hepatitis C cure wins prestigious award from University of Edinburgh

A medicinal chemist who found a cure for the viral disease hepatitis C has received a prestigious award from the University of Edinburgh.

3 May 2020

New study could improve our understanding about platelets

University of Kentucky College of Medicine researcher Sidney Whiteheart has been awarded a prestigious Outstanding Investigator Award from the National Heart, Blood and Lung Institute for his research on how platelets function in hemostasis and during immune responses.

29 Apr 2020

Kurome secures license to develop novel therapies for chemo-resistant cancer

Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.